lapatinib has been researched along with desipramine in 7 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (desipramine) | Trials (desipramine) | Recent Studies (post-2010) (desipramine) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 5,775 | 487 | 414 |
| Protein | Taxonomy | lapatinib (IC50) | desipramine (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 1 | Homo sapiens (human) | 9.18 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.35 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0003 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.35 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0034 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0003 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0003 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.35 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.0031 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 7.8 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.35 | |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.35 | |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.35 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.35 | |
| 5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | 0.35 | |
| Histamine H1 receptor | Rattus norvegicus (Norway rat) | 0.0008 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.1961 | |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | 0.35 | |
| 5-hydroxytryptamine receptor 5A | Rattus norvegicus (Norway rat) | 0.35 | |
| 5-hydroxytryptamine receptor 5B | Rattus norvegicus (Norway rat) | 0.35 | |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | 0.35 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0003 | |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | 3.8 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 9.9 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.4035 | |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 1.52 | |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | 0.35 | |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | 0.35 | |
| Solute carrier family 22 member 2 | Rattus norvegicus (Norway rat) | 10 | |
| Transporter | Rattus norvegicus (Norway rat) | 7.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Buckley, DB; Funk, RS; Hensley, T; Kazmi, F; Loewen, GJ; Parkinson, A; Pope, C | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
1 review(s) available for lapatinib and desipramine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for lapatinib and desipramine
| Article | Year |
|---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
Topics: Adrenergic beta-Antagonists; Amines; Ammonium Chloride; Antidepressive Agents, Tricyclic; Atorvastatin; Cell Line, Transformed; Diuretics; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imipramine; Lysosomes; Monensin; Nigericin; Propranolol; Pyrroles | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |